Prednisolone or pentoxifylline for alcoholic hepatitis

Area of Science:

• Hepatology
• Clinical Medicine
• Gastroenterology

Background:

• Alcoholic hepatitis is a severe liver condition with high short-term mortality.
• Current treatments like prednisolone and pentoxifylline have uncertain efficacy.

Purpose of the Study:

• To evaluate the effectiveness of prednisolone and pentoxifylline in treating severe alcoholic hepatitis.
• To assess their impact on short-term and long-term mortality.

Main Methods:

• A multicenter, double-blind, randomized trial with a 2x2 factorial design.
• Patients received prednisolone, pentoxifylline, both, or placebo.
• Primary endpoint was 28-day mortality; secondary endpoints included 90-day and 1-year mortality and liver transplantation.

Main Results:

• No significant difference in 28-day mortality between pentoxifylline and placebo groups (OR 1.07, P=0.69).
• Prednisolone showed a non-significant trend toward reduced 28-day mortality (OR 0.72, P=0.06).
• Serious infections were more frequent in patients receiving prednisolone (13% vs 7%, P=0.002).

Conclusions:

• Pentoxifylline is not effective in improving survival for alcoholic hepatitis.
• Prednisolone did not significantly improve survival at 28 days, 90 days, or 1 year and was associated with increased infection risk.